JP2010510234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510234A5 JP2010510234A5 JP2009537359A JP2009537359A JP2010510234A5 JP 2010510234 A5 JP2010510234 A5 JP 2010510234A5 JP 2009537359 A JP2009537359 A JP 2009537359A JP 2009537359 A JP2009537359 A JP 2009537359A JP 2010510234 A5 JP2010510234 A5 JP 2010510234A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- hcv
- aryl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims 3
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86613006P | 2006-11-16 | 2006-11-16 | |
| US60/866,130 | 2006-11-16 | ||
| US11/939,780 US7888464B2 (en) | 2006-11-16 | 2007-11-14 | Hepatitis C virus inhibitors |
| US11/939,780 | 2007-11-14 | ||
| PCT/US2007/084799 WO2008064066A1 (en) | 2006-11-16 | 2007-11-15 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510234A JP2010510234A (ja) | 2010-04-02 |
| JP2010510234A5 true JP2010510234A5 (enExample) | 2010-12-24 |
| JP5241729B2 JP5241729B2 (ja) | 2013-07-17 |
Family
ID=39247306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537359A Expired - Fee Related JP5241729B2 (ja) | 2006-11-16 | 2007-11-15 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7888464B2 (enExample) |
| EP (1) | EP2086995B1 (enExample) |
| JP (1) | JP5241729B2 (enExample) |
| KR (1) | KR20090083462A (enExample) |
| AT (1) | ATE546460T1 (enExample) |
| AU (1) | AU2007323793A1 (enExample) |
| BR (1) | BRPI0719008A2 (enExample) |
| CA (1) | CA2669856A1 (enExample) |
| CO (1) | CO6190510A2 (enExample) |
| EA (1) | EA015827B1 (enExample) |
| ES (1) | ES2381308T3 (enExample) |
| IL (1) | IL198741A0 (enExample) |
| MX (1) | MX2009004943A (enExample) |
| NO (1) | NO20091871L (enExample) |
| NZ (1) | NZ576814A (enExample) |
| WO (1) | WO2008064066A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| CA2676297A1 (en) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim International Gmbh | Inhibitors of hepatitis c ns3 protease |
| JP5647790B2 (ja) * | 2007-11-16 | 2015-01-07 | 株式会社カネカ | Ｎ−カルバモイル−ｔｅｒｔ−ロイシンの製造法 |
| MX2010006210A (es) * | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hcv de tripeptido fluorado. |
| US8501682B2 (en) * | 2008-01-24 | 2013-08-06 | Enanta Pharmaceuticals, Inc. | Difluorinated tripeptides as HCV serine protease inhibitors |
| US8372802B2 (en) * | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8283310B2 (en) * | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| JP2012532146A (ja) * | 2009-07-02 | 2012-12-13 | ドクター・レディーズ・ラボラトリーズ・リミテッド | アミノビニルシクロプロパンカルボン酸誘導体の分割のための酵素および方法 |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| CN103124722B (zh) * | 2010-09-22 | 2014-11-12 | 三井化学Agro株式会社 | 具有含氟氨基甲酸酯基的氨基酸酰胺衍生物的制造方法、其制造中间体、及乙二胺衍生物的制造方法 |
| WO2012087833A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Hepatitis c inhibitors and uses thereof |
| US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
| JP2014502620A (ja) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| WO2013190509A2 (en) * | 2012-06-22 | 2013-12-27 | Dr.Reddys Laboratories Limited | Preparation of intermediates of boceprevir |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| CN105073758B (zh) | 2013-03-15 | 2017-08-11 | 吉利德科学公司 | 丙型肝炎病毒抑制剂 |
| CN103396344B (zh) * | 2013-08-08 | 2014-10-29 | 苏州永健生物医药有限公司 | 一锅法合成n-叔丁氨羰基-3-甲基-l-缬氨酸的方法 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子 |
| DE69829381T2 (de) | 1997-08-11 | 2006-04-13 | Boehringer Ingelheim (Canada) Ltd., Laval | Hepatitis c inhibitor peptide |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| MXPA03000627A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| AU2003248535A1 (en) | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| EP1505945B1 (en) | 2002-05-20 | 2008-11-05 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| JP4312718B2 (ja) | 2002-05-20 | 2009-08-12 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| EP1601685A1 (en) | 2003-03-05 | 2005-12-07 | Boehringer Ingelheim International GmbH | Hepatitis c inhibiting compounds |
| WO2004101602A2 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| CA2520886A1 (en) | 2003-04-02 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| PL1615613T3 (pl) | 2003-04-18 | 2010-04-30 | Enanta Pharm Inc | Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C |
| UY28323A1 (es) | 2003-05-21 | 2004-12-31 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| JP4704342B2 (ja) | 2003-09-22 | 2011-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスに対し活性な大環状ペプチド |
| CA2541634A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2546290A1 (en) | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスに対して活性な大環状ペプチド |
| AR047793A1 (es) | 2004-01-30 | 2006-02-22 | Medivir Ab | Inhibidores de la serina proteasa ns-3 del vhc |
| WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| JP5156374B2 (ja) | 2004-05-25 | 2013-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非環式ｈｃｖプロテアーゼインヒビターの調製方法 |
| JP4914348B2 (ja) | 2004-06-28 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| PL382845A1 (pl) | 2004-07-16 | 2008-01-21 | Gilead Sciences, Inc. | Związki przeciwwirusowe |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| US7550559B2 (en) | 2004-08-27 | 2009-06-23 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease |
| CA2577831A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| US20070249637A1 (en) | 2004-10-21 | 2007-10-25 | Collins Michael R | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2332963A3 (en) | 2005-03-08 | 2011-11-16 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006130553A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| WO2006130627A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
| PE20070011A1 (es) | 2005-06-02 | 2007-03-08 | Schering Corp | Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina |
| JP2008545748A (ja) | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130626A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| CA2615921C (en) | 2005-07-20 | 2011-09-13 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety |
| US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| PL1919899T3 (pl) | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
| BRPI0614621A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos de vìrus da hepatite c |
| EP1919904B1 (en) | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| WO2007017144A2 (en) | 2005-07-29 | 2007-02-15 | Medivir Ab | Macrocylic inhibitors of hepatitis c virus |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| WO2007014924A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| JP5230417B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大員環インヒビター |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| MY144607A (en) | 2005-07-29 | 2011-10-14 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
| JP4705984B2 (ja) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド |
| WO2007016476A2 (en) | 2005-08-01 | 2007-02-08 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| CA2644389A1 (en) | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
-
2007
- 2007-11-14 US US11/939,780 patent/US7888464B2/en active Active
- 2007-11-15 EP EP07864446A patent/EP2086995B1/en active Active
- 2007-11-15 KR KR1020097012336A patent/KR20090083462A/ko not_active Withdrawn
- 2007-11-15 NZ NZ576814A patent/NZ576814A/en not_active IP Right Cessation
- 2007-11-15 WO PCT/US2007/084799 patent/WO2008064066A1/en not_active Ceased
- 2007-11-15 ES ES07864446T patent/ES2381308T3/es active Active
- 2007-11-15 CA CA002669856A patent/CA2669856A1/en not_active Abandoned
- 2007-11-15 MX MX2009004943A patent/MX2009004943A/es active IP Right Grant
- 2007-11-15 BR BRPI0719008-5A2A patent/BRPI0719008A2/pt not_active IP Right Cessation
- 2007-11-15 AU AU2007323793A patent/AU2007323793A1/en not_active Abandoned
- 2007-11-15 JP JP2009537359A patent/JP5241729B2/ja not_active Expired - Fee Related
- 2007-11-15 EA EA200900697A patent/EA015827B1/ru not_active IP Right Cessation
- 2007-11-15 AT AT07864446T patent/ATE546460T1/de active
-
2009
- 2009-05-13 NO NO20091871A patent/NO20091871L/no not_active Application Discontinuation
- 2009-05-14 IL IL198741A patent/IL198741A0/en unknown
- 2009-05-15 CO CO09049882A patent/CO6190510A2/es not_active Application Discontinuation